Avonex Boasts Superior Adherence Rates
This article was originally published in The Pink Sheet Daily
Patients taking Biogen’s MS therapy stuck to their regimen better than those taking Rebif, Betaferon or Copaxone in a global study, Biogen reports.
You may also be interested in...
In Phase II studies, 77% of patients treated with Novartis' FTY720 remained relapse free after two years.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.